

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
Karachi

No.2/2/2003-F.Sec.

Dated: 25-1-2008

To,

The Manager,  
Printing Corporation of Pakistan Press,  
University Road,  
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 10-11-2007 TO BE PUBLISHED ON 26-1-2007 IN  
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1284/2007	<b><u>05-11-2007</u></b> Novartis AG. Switzerland. Priority (07-11-2006 EP)	“Organic compounds”
1285/2007	<b><u>06-11-2007</u></b> Mr. Yoshio Oyama. Japan. Priority (07-11-2006 Japan)	“An ampoule having a structure capable of easily obtaining a beautiful aperture plane by cleavage and a movable gasket”
1286/2007	Spray Engineering Devices Limited. India. Priority (17-11-2006 India)	“Heat exchanger assembly”
1287/2007	Mr. Yoshio Oyama. Japan. Priority (07-11-2006 Japan)	“An ampoule guide and a drug solution administering unit”
1288/2007	Unistraw Patent Holdings Limited. Malaysia. Priority (06-11-2006 Australia)	“Functional filter for drinking straw”
1289/2007	The General Hospital Corporation. USA. Priority (07-11-2006 USA)	“Attenuation of vocative oxygen carrier-induced vasoconstriction”
1290/2007	AstraZeneca AB. Sweden. Priority (10-11-2006 USA)	“Chemical compounds”
1291/2007	Media Work Table AG. Switzerland. Priority (09-11-2006 DE)	“Deposition device”
1292/2007	Media Work Table AG. Switzerland. Priority (09-11-2006 DE)	“Deposition device”
1293/2007	Media Work Table AG. Switzerland. Priority (09-11-2006 DE)	“Deposition device”
1294/2007	AstraZeneca AB. Sweden. Priority (10-11-2006 USA)”	“Chemical compounds”
1295/2007	Novelties AG. Switzerland. Priority (09-11-2006 EP)	“New salt”

1296/2007	Dominative Performance Materials Inc. USA. Priority (14-11-2006 USA)	“Process for crosslinking thermoplastic polymers with silanes employing peroxide blends, the resulting cross linked thermoplastics polymer composition and articles made therefrom”
1297/2007	Schering Corporation. USA. Priority (08-11-2006 USA)	“Imidazopyrazine as protein kinase inhibitors”
1298/2007	DSM IP Assets B.V. Netherlands. Priority (09-11-2006 EP)	“Process for the preparation of a panel”
1299/2007	Genentech, Inc. USA. Priority (07-11-2006 USA)	“Tissue plasminogen activator variant uses”
1300/2007	H. Lundbeck A/S. Denmark. Priority (22-06-2006 USA)	“Alkyl sulfonamide derivatives”
1301/2007	<b><u>07-11-2007</u></b> Reckitt Benckiser (UK)Limited, United Kingdom. Priority (07-11-2006 UK)	“Method and device for spraying a fluid form a container”
1302/2007	Reckitt Benckiser (UK) Limited. United Kingdom. Priority (07-11-2006 UK)	“Device for evaporating a volatile liquid”
1303/2007	Basf Aktiengesellschaft Germany. Priority (24-04-2006 USA)	“Process for the sulfinylation of a pyrazole derivative”
1304/2007	Acambis Inc. USA. Priority (07-11-2006 USA)	Stabilization of vaccines by lyophilization”
1305/2007	<b><u>08-11-2007</u></b> Sanofi-Aventis. France. Priority (10-11-2006 France)	“Substituted pyrazoles, compositions containing same, manufacturing process therefore and use thereof”
1306/2007	IRM LLC. Bermuda. Priority (09-11-2006)	“Agonist trkb antibodies and uses thereof”
1307/2007	Centelion . France. Priority (28-11-2006 EP)	“Modified soluble FGF receptor Fe fusions with improved biological activity”
1308/2007	1. Yung-Ching Chen. 2. Chih-Chieh Chen. Taiwan	“Engine”

1309/2007	Bristol-Myers Squibb Company. USA. Priority (09-11-2006 USA)	“Hepatitis C virus inhibitors”
1310/2007	Bristol-Myers Squibb Company. USA. Priority (08-11-2006 USA)	Pyridinone compounds”
1311/2007	Bayer Schering Pharma Aktiengesellschaft. Germany. Priority (15-11-2006 DE)	“Progesterone receptor antagonists”
1312/2007	Wyeth. USA. Priority (10-11-2006 USA)	“N-substituted piperidinyl 4-arylsulfonamides and methods of their use”
1313/2007	Wyeth. USA. Priority (08-11-2006 USA)	“Rationally designed media for cell culture”
1314/2007	<b><u>10-11-2007</u></b> Pfizer Products Inc. USA. Priority (13-11-2006 USA)	“Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof “
1315/2007	Sanofi-Aventis. France. Priority (23-11-2006 France)	“Substituted 2,5-Dihydro-3H-pyrazolo[4,3- C]pyridazin-3-one derivatives, preparation thereof and therapeutic use thereof”

### APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


260/2002 F. Hoffmann-La Roche  
Switzerland

“Dihydro-benzo [ 1, 4 ] diazepin-2-one compound as  
mGluR2 antagonist 1”

(C07D, 243/14)

139325

This invention is concerned with dihydro-benzo  
[b][1,4] diazepin -2-one derivatives of the general  
formula.



Wherein R1, R2, R3 and Y are as defined in the  
specification. The invention further relates to  
medicaments containing these compounds, a process  
for their preparation as well as their use for preparation  
of medicaments for the treatment or prevention of  
acute and/or chronic neurological disorders”